Computational Drug Discovery and Repurposing for the Treatment of COVID-19: A Systematic Review
151
TL;DR: A list of existing drugs that have the potential to influence SARS-CoV2 through different mechanisms of action are provided, including antiviral drugs commonly used to treat AIDS/HIV, and Ebola.
read more
About: This article is published in Bioorganic Chemistry. The article was published on 01 Jan 2021. and is currently open access. The article focuses on the topics: Repurposing.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
The American journal of emergency medicine
ScienceDirect
- 01 Jan 1983
TL;DR: Covering all activities concerned with emergency medicine, it is the journal to turn to for information to help increase the ability to understand, recognize and treat emergency conditions.
369
Use of molecular docking computational tools in drug discovery.
TL;DR: In this article, the authors provide an introduction to molecular docking and to the different docking procedures with a focus on several considerations and protocols, including protonation states, active site waters and consensus, that can greatly improve the docking results.
323
Structural biology of SARS-CoV-2: open the door for novel therapies
TL;DR: In this paper , a review summarizes representative structures and typically potential therapy agents that target SARS-CoV-2 or some critical proteins for viral pathogenesis, providing insights into the mechanisms underlying viral infection, prevention of infection, and treatment.
References
Potential Inhibitors Against Papain-like Protease of Novel Coronavirus (COVID-19) from FDA Approved Drugs
Rimanshee Arya,Amit Das,Vishal Prashar,Mukesh Kumar +3 more
TL;DR: This study identifies 15 FDA-approved drugs, including chloroquine and formoterol, as potential inhibitors of the papain-like protease of COVID-19, suggesting their utility in treating the disease through in silico docking studies.
The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future.
TL;DR: The epidemic and etiological characteristics of 2019-nCoV are described, its essential biological features, including tropism and receptor usage, are discussed, approaches for disease prevention and treatment are summarized, and speculation on the transmission route is speculated.
High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase.
Jan E. Blanchard,Nadine H. Elowe,Carly Huitema,Pascal D. Fortin,Jonathan Cechetto,Lindsay D. Eltis,Eric D. Brown +6 more
TL;DR: This data indicates that the main proteinase of SARS-CoV, 3CLpro, is an attractive target for therapeutics against SARS owing to its fundamental role in viral replication, and five novel small molecules that show potent inhibitory activity toward 3CL Pro are identified.
Novel computational approaches to polypharmacology as a means to define responses to individual drugs.
TL;DR: Recent progress and challenges in computational techniques that enable the prediction and analysis of in vitro and in vivo drug-response phenotypes are reviewed.
Related Papers (5)
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more